Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/accelerating-drug-development-antiviral-therapies-for-emerging-viruses-Z6oEGQOY0v
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2017 by Annual Reviews. All rights reserved
- ISSN
- 0362-1642
- eISSN
- 1545-4304
- DOI
- 10.1146/annurev-pharmtox-010716-104533
- pmid
- 27483339
- Publisher site
- See Article on Publisher Site
Abstract
Drug discovery and development is a lengthy and expensive process. Although no one, simple, single solution can significantly accelerate this process, steps can be taken to avoid unnecessary delays. Using the development of antiviral therapies as a model, we describe options for acceleration that cover target selection, assay development and high-throughput screening, hit confirmation, lead identification and development, animal model evaluations, toxicity studies, regulatory issues, and the general drug discovery and development infrastructure. Together, these steps could result in accelerated timelines for bringing antiviral therapies to market so they can treat emerging infections and reduce human suffering.
Journal
Annual Review of Pharmacology and Toxicology – Annual Reviews
Published: Jan 6, 2017